By Denny Jacob
LifeMD shares surged 22% after announcing plans to offer access to semaglutide, which is marketed as Wegovy to treat obesity, through NovoCare Pharmacy.
Shares were trading around $7.49. The stock is down 49% on the year.
The virtual primary care services provider said the addition of direct access to Wegovy provides a brand-name GLP-1 option at a recently reduced self-pay cost of $499 a month. It added that all doses of Wegovy are available in a pen device to eligible LifeMD patients who are uninsured or whose insurance doesn't cover prescription weight-loss medications.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 29, 2025 08:53 ET (12:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。